跳至主要内容
临床试验/NCT01394666
NCT01394666已完成不适用

Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily

Bristol-Myers Squibb0 个研究点目标入组 150 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150
主要终点
Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily

研究概览

简要总结

The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.

详细描述

Time Perspective: Retrospective and Prospective

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult patients (18 years or older) in Chronic phase CML patients who have been treated with Imatinib 400 mg and have failed.

排除标准

  • 未提供

结局指标

主要结局

Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily

时间窗: At 12 months post treatment change

次要结局

  • Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily(12 months after start of treatment)
  • Best response rates achieved by patients if no CCyR(12 months after start of treatment)

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry
责任方
Sponsor

相似试验

Non-interventional Treatment Patterns Study in... | 临床试验